1
In inflammatory bowel disease (IBD), the stakes of every treatment decision are high. Patients live with a chronic, often unpredictable condition that can upend daily life—missing work or school and coping with pain, fatigue, and anxiety about the next flare. Over the past decade, biologic therapies have transformed the IBD landscape, helping many patients achieve remission and reclaim a sense of normalcy. But as patents on these biologics expire, biosimilars—highly similar, more affordable versions—are rapidly reshaping treatment pathways, formularies, and conversations at the clinic level.
That shift brings both opportunity and uncertainty….